In:
Rheumatology, Termedia Sp. z.o.o., Vol. 51, No. 5 ( 2013-10-30), p. 370-374
Abstract:
Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology, characterized by inflammation of the symmetrical joints, multi-organ complications, flares and complete or partial remission periods, which results in disability and increased mortality. Methotrexate (MTX) remains the first-line therapy for active RA. In red blood cells (RBC) MTX is transformed into methotrexate polyglutamates (MTXPG). Disease activity and treatment results are strongly associated with methotrexate polyglutamate concentrations in red blood cells. The article presents the correlation between the route of administration of the treatment, RBC MTXPG concentration and disease activity in patients with rheumatoid arthritis. Also, the impact of genetic polymorphism in the folate-purine-pyrimidine pathway on effects of MTX therapy is stressed.
Type of Medium:
Online Resource
ISSN:
0034-6233
,
2084-9834
Uniform Title:
Stężenie metotreksatu w erytrocycie a aktywność procesu chorobowego u chorych na reumatoidalne zapalenie stawów
DOI:
10.5114/reum.2013.38389
Language:
Polish
Publisher:
Termedia Sp. z.o.o.
Publication Date:
2013
detail.hit.zdb_id:
2233668-0
Bookmarklink